Merck Announces Presentations of Clinical and Real-World Data at The Alzheimer’s Association International Conference®
July 17 2017 - 7:00AM
Business Wire
Merck (NYSE:MRK), known as MSD outside of the United States and
Canada, today announced the presentation of data at The Alzheimer’s
Association International Conference taking place in London, July
16–20, 2017.
"Alzheimer’s disease remains one of the most daunting medical
issues of our time –for individuals and their families, for the
scientific and medical communities, and for public health,” said
Darryle Schoepp, vice president, neuroscience discovery, Merck
Research Laboratories. "Merck has extensive research underway to
develop novel medicines for Alzheimer’s disease, and to improve
understanding of the science and impact of this devastating
disease."
Notable abstracts to be presented at The Alzheimer’s Association
International Conference® include:
Saturday, July 15
- First Evaluation of the Neurofibrillary
Tangles Radioligand [18F]MK-6240 in AD Patients (Poster
presentation, Abstract IC-P-177, 12:15 p.m. – 1:30 p.m. BST)
- In Vitro Binding Studies to Evaluate
the NFT-Specificity of [3H]MK-6240 and [3H]AV-1451 Binding in
Subcortical Regions of Human AD Brain (Poster presentation,
Abstract IC-P-207, 12:15 p.m. – 1:30 p.m. BST)
Sunday, July 16
- The Race to Diagnose: Disease Severity
As a Factor of AD Diagnosis (Poster presentation, Abstract P1-565,
9:30 a.m. – 4:15 p.m. BST)
- Episode of Care Among AD Patients Newly
Diagnosed in Inpatient Setting in the U.S. Medicare Population
(Poster presentation, Abstract P1-590, 9:30 a.m. – 4:15 p.m.
BST)
- Systems Pharmacology Analysis of the Aβ
Oligomer Response Following BACE1 Inhibition: Evidence for
Second-Order Aβ42 Oligomerization (Poster presentation, Abstract
P1-108, 9:30 a.m. – 4:15 p.m. BST)
Monday, July 17
- Comparison of Healthcare Costs for AD
Patients Diagnosed in Inpatient Versus Non-Inpatient Setting
(Poster presentation, Abstract P2-558, 9:30 a.m. – 4:15 p.m.
BST)
- Health Care Use Among Newly Diagnosed
AD Patients in a U.S. Commercial Medicare Advantage Insurance Plan
(Poster presentation, Abstract P2-557, 9:30 a.m. – 4:15 p.m.
BST)
- Resilience Mechanism of the Amyloid
Precursor Protein (APP) Pathway Revealed By Systems Pharmacology
Modeling Following β- and γ-Secretase Inhibition (Poster
presentation, Abstract P2-066, 9:30 a.m. – 4:15 p.m. BST)
- Acute Administration of a BACE
Inhibitor in Healthy Humans Results in a Significant Reduction of
Aβ Oligomers in Cerebrospinal Fluid (Oral presentation, Abstract
O2-09-01, 2:00 p.m. – 2:15 p.m. BST)
Tuesday, July 18
- Phenotypic Screening for Novel
Inhibitors of Tau Aggregation in Human iPSC-Derived Neurons (Poster
presentation, P3-083, 9:30 a.m. – 4:15 p.m. BST)
- Real-World Administration of the AD
Assessment Scale-Cognitive (Poster presentation, Abstract P3-253,
9:30 a.m. – 4:15 p.m. BST)
Wednesday, July 19
- Health Care Use Among Newly Diagnosed
AD Patients in a U.S. Database of Employer-Sponsored Medicare
Supplement Insurance Plans (Poster presentation, Abstract P4-358,
9:30 a.m. – 4:15 p.m. BST)
- An Analytic Method to Address the
Non-Linearity Form of AD Modifying Model (Poster presentation,
Abstract P4-204, 9:30 a.m. – 4:15 p.m. BST)
- Potentiation of Tau Pathology By the
ApoEε4 Dementia Risk Allele (Poster presentation, Abstract P4-111,
9:30 AM – 4:15 PM BST)
Thursday, July 20
- Leveraging Medicare Claims to
Characterize Diagnostic Pathways in AD (Oral presentation, Abstract
O5-03-03, 12:15 p.m. – 12:30 p.m. BST)
For more information, including a list of abstract titles,
please visit: https://www.alz.org/aaic/.
About Merck’s Commitment to Alzheimer’s Disease
For more than 10 years, Merck has been researching different
ways to treat Alzheimer’s disease. In addition to our dedicated
internal research efforts, we are driving innovation in
collaboration with others and leveraging the latest innovations in
brain imaging technology in order to help identify individuals in
the early stages of Alzheimer’s disease. Merck is working to
improve our understanding of the disease to help those living with
Alzheimer’s and their loved ones around the world.
About Merck
For more than a century, Merck, a leading global
biopharmaceutical company known as MSD outside of the United States
and Canada, has been inventing for life, bringing forward medicines
and vaccines for many of the world’s most challenging diseases.
Through our prescription medicines, vaccines, biologic therapies
and animal health products, we work with customers and operate in
more than 140 countries to deliver innovative health solutions. We
also demonstrate our commitment to increasing access to health care
through far-reaching policies, programs and partnerships. Today,
Merck continues to be at the forefront of research to advance the
prevention and treatment of diseases that threaten people and
communities around the world - including cancer, cardio-metabolic
diseases, emerging animal diseases, Alzheimer’s disease and
infectious diseases including HIV and Ebola. For more information,
visit www.merck.com and connect with us
on Twitter, Facebook, Instagram, YouTube
and LinkedIn.
Forward-Looking Statement of Merck & Co., Inc.,
Kenilworth, N.J., USA
This news release of Merck & Co., Inc., Kenilworth, N.J.,
USA (the “company”) includes “forward-looking statements” within
the meaning of the safe harbor provisions of the U.S. Private
Securities Litigation Reform Act of 1995. These statements are
based upon the current beliefs and expectations of the company’s
management and are subject to significant risks and uncertainties.
There can be no guarantees with respect to pipeline products that
the products will receive the necessary regulatory approvals or
that they will prove to be commercially successful. If underlying
assumptions prove inaccurate or risks or uncertainties materialize,
actual results may differ materially from those set forth in the
forward-looking statements.
Risks and uncertainties include but are not limited to, general
industry conditions and competition; general economic factors,
including interest rate and currency exchange rate fluctuations;
the impact of pharmaceutical industry regulation and health care
legislation in the United States and internationally; global trends
toward health care cost containment; technological advances, new
products and patents attained by competitors; challenges inherent
in new product development, including obtaining regulatory
approval; the company’s ability to accurately predict future market
conditions; manufacturing difficulties or delays; financial
instability of international economies and sovereign risk;
dependence on the effectiveness of the company’s patents and other
protections for innovative products; and the exposure to
litigation, including patent litigation, and/or regulatory
actions.
The company undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events or otherwise. Additional factors that could cause
results to differ materially from those described in the
forward-looking statements can be found in the company’s 2016
Annual Report on Form 10-K and the company’s other filings with the
Securities and Exchange Commission (SEC) available at the SEC’s
Internet site (www.sec.gov).
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170717005295/en/
MerckMedia:Pamela Eisele, 267-305-3558orIan McConnell,
973-901-5722orInvestors:Teri Loxam, 908-740-1986orAmy Klug,
908-740-1898
Merck (NYSE:MRK)
Historical Stock Chart
From Aug 2024 to Sep 2024
Merck (NYSE:MRK)
Historical Stock Chart
From Sep 2023 to Sep 2024